clinical trial · NCT07220616
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Daiichi Sankyo·phase2·recruiting·n = 420
Hematological MalignanciesDS3790aCombination drugCombination drug
brief summary
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
started
Jan 16, 2026
primary completion
Nov 30, 2030
completion
Nov 30, 2030
last updated
Mar 18, 2026
detailed description
DS3790a may be effective in the treatment of patients with hematological malignancies. The primary objective of this study will assess the safety and preliminary efficacy of DS3790a monotherapy and combination regimens.
official title
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, for Hematological Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol